All In Biotech

Drug Trial Radar · NCT05626959

Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder

A Phase II/III Double-Blind, Randomised and Controlled-to-Open-Label Study Assessing the Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) on the Severity of Autism Spectrum Disorder in Young People

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

54

Actual

Start

Nov 30, 2022

Primary completion

Mar 1, 2024

Study completion May 30, 2026

Sponsor

Lead sponsor
Fenix Innovation GroupIndustry
Sponsor type
Industry
Collaborators
Neurotech International Limited; Monash Health
First posted
Nov 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 8 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an 18 to 54 week study assessing the efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) on the severity of autism spectrum disorder in young people.

Conditions

  • Autism Spectrum Disorder

Interventions

  • NTI164Drug

    Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Clinical Global Impression-Severity (CGI-S)Time frame: Baseline, Week 8.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Monash Children's Hospital

    Clayton, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.